redox status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Glutathione serves as a cofactor for several enzymes, including glutathione peroxidase and glutathione S-transferase. These enzymes help reduce hydrogen peroxide and lipid peroxides, and they conjugate reactive electrophiles for excretion. The molecule also acts as a reservoir for cysteine, an amino acid that is prone to oxidation. In addition, glutathione participates in the metabolism of nitric oxide, leukotrienes, and prostaglandins. Its roles extend to cell signaling, apoptosis, and the regulation of protein function through S-glutathionylation.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine, and it is the most abundant non-protein thiol in most living cells. The reduced form, GSH, carries a sulfhydryl group that can donate electrons, while the oxidized form, GSSG, forms when two GSH molecules link via a disulfide bond. The balance between these two forms helps define the cellular redox environment, and their ratio is often used as an indicator of oxidative stress. Because the sulfhydryl group is reactive, glutathione participates in many cellular processes, including detoxification and protein regulation.
Glutathione supports several cellular processes beyond direct antioxidant action. It serves as a cofactor for glutathione peroxidase and glutathione S-transferase enzymes, which reduce peroxides and conjugate electrophiles, respectively. The molecule also acts as a reservoir of cysteine, an amino acid that can limit protein synthesis and redox signaling. In human nutrition, oral glutathione is sold as a supplement, but how much intact glutathione reaches tissues after ingestion remains an active research question. Clinical claims about supplementation are not uniformly supported by controlled trials.
Glutathione is a small tripeptide built from glutamic acid, cysteine, and glycine. Its peptide bond between glutamate and cysteine involves the gamma-carboxyl group rather than the usual alpha-carboxyl group. This structure gives the molecule a reactive thiol on the cysteine residue. The reduced form, often abbreviated GSH, is the predominant intracellular species in many cell types. Because the thiol can donate electrons, glutathione participates in redox chemistry and in the conjugation of reactive molecules.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Reduced form (GSH) |
| Molar mass | 307.32 g/mol | For GSH; GSSG is 612.63 g/mol |
| Appearance | White crystalline powder | Usually lyophilized |
| Solubility in water | Freely soluble (≥100 mg/mL) | pH dependent |
| Typical storage | -20 °C, desiccated | Protect from light and oxygen |
Stability depends on pH, temperature, oxygen exposure, and trace metals. Aqueous solutions of reduced glutathione are susceptible to oxidation, especially when neutral or alkaline and exposed to air. Transition metal ions can catalyze thiol oxidation, so chelators and inert atmospheres are sometimes used in research settings. Standards are typically stored cold and desiccated, with limited freeze-thaw cycles. Questions remain about how closely in vitro stability data reflect the behavior of glutathione within intact cells and tissues.
Measuring glutathione requires attention to oxidation during sample handling, because GSH in biological samples can convert to GSSG or form mixed disulfides with proteins after collection. Acidic extraction, rapid cooling, and chelating agents are commonly used to limit such changes. Analytical methods usually distinguish free reduced glutathione, total glutathione, and protein-bound forms. Because these forms have different stability and reactivity, reported values depend heavily on the preparation protocol. No single preparation is universally suitable for every biological matrix or analytical goal.
Several techniques are used for quantification. Enzymatic recycling assays rely on glutathione reductase and a colorimetric or fluorescent readout, offering sensitivity for total glutathione. High-performance liquid chromatography can separate GSH from GSSG and other thiols, often with UV, fluorescence, or electrochemical detection. Mass spectrometry provides structural confirmation and can quantify low-abundance species when paired with separation. Each approach has trade-offs in specificity, throughput, and equipment requirements, so method selection depends on the research question and available instrumentation.
Functionally, glutathione supports redox balance by donating electrons and becoming oxidized. It also serves as a cofactor for enzymes such as glutathione peroxidases and glutathione S-transferases. These enzymes participate in peroxide reduction and in conjugation reactions that help process reactive molecules. Separate from antioxidant roles, glutathione can modify protein cysteines through S-glutathionylation, influencing enzyme activity and signaling. Research continues to examine how these chemical roles translate into whole-organism effects.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its glutamate-cysteine linkage uses the gamma-carboxyl group of glutamate, a feature that resists standard peptidases. The cysteine residue provides a thiol group, which gives the molecule its reducing character. In cells, glutathione is often the most abundant small-molecule thiol, with concentrations varying widely by tissue and compartment. It exists mainly in a reduced form called GSH, while oxidation produces a disulfide-linked dimer called GSSG.
Biosynthesis proceeds in two ATP-dependent steps. First, glutamate-cysteine ligase joins glutamate and cysteine. Second, glutathione synthetase adds glycine to the intermediate. The pathway is regulated by cysteine availability, enzyme expression, and feedback inhibition by glutathione itself. Liver tissue has a particularly high capacity for synthesis and export. Because the molecule is made inside cells, circulating glutathione reflects a balance of release, uptake, and breakdown rather than simple dietary supply.
Quality control for glutathione measurements includes calibration with authenticated standards, internal standards where available, blank correction, and spike recovery checks. Because glutathione can form during sample processing or degrade before analysis, pre-analytical handling is a major source of variability. Interlaboratory comparisons often show differences in reported values due to method-specific calibration and detection principles. Interpretive thresholds are context-dependent, and no single reference range applies across all tissues or matrices. Researchers generally report both reduced and oxidized forms, along with the method and sample handling details.
Quantification of glutathione in biological or food samples commonly uses liquid chromatography coupled to ultraviolet, fluorescence, electrochemical, or mass spectrometric detection. Because the thiol group oxidizes readily, samples are often acidified or derivatized immediately after collection to stabilize reduced glutathione. Enzymatic recycling assays and colorimetric kits offer higher throughput but generally lower specificity than chromatographic methods. Mass spectrometry can distinguish glutathione from related thiols and allow simultaneous measurement of oxidized forms. Reported concentrations depend strongly on sample type, extraction procedure, and analytical platform.
Glutathione reference materials are sensitive to oxygen, light, and elevated temperature. Solid material is typically stored desiccated at -20 °C or below, while solutions require tighter control because thiol oxidation proceeds faster in liquid form. Aqueous solutions are often prepared fresh, kept cold, and protected from air; some protocols add acid or chelating agents to slow metal-catalyzed oxidation. Repeated freeze-thaw cycles can accelerate degradation and should be avoided. Stability data vary by matrix, so laboratories usually verify performance with their own storage conditions.
Glutathione synthesis proceeds in two ATP-dependent steps catalyzed by glutamate-cysteine ligase and glutathione synthetase. The first step joins glutamate and cysteine to form gamma-glutamylcysteine and is generally rate-limiting. The second step adds glycine to complete the tripeptide. Cysteine availability, feedback inhibition by glutathione, and oxidative conditions influence flux through this pathway. The pathway is conserved across many organisms, and degradation by gamma-glutamyl transpeptidase and related peptidases recycles amino acids for new synthesis.
Within cells, glutathione serves as a cofactor for glutathione peroxidases and glutathione S-transferases. These enzymes reduce hydrogen peroxide and organic peroxides or conjugate electrophilic compounds to the thiol group. The resulting conjugates can be exported and processed through mercapturic acid pathways. Glutathione also contributes to protein thiol homeostasis and to recycling of other antioxidants such as ascorbate. Its precise roles vary by tissue, and many regulatory effects observed in laboratory systems remain difficult to quantify in whole organisms.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It occurs in nearly all living cells, with highest concentrations in liver, kidney, and red blood cells, and exists in reduced (GSH) and oxidized disulfide (GSSG) forms. The cysteine thiol group enables reversible oxidation and reduction reactions. This property makes glutathione a central participant in cellular redox balance. The balance between these forms is often used as an indicator of oxidative stress.
Early experiments resembling activity-based profiling were conducted in the 1970s, when small molecules were used to study the mechanism of action of the serine-modifying antibiotic penicillin. The modern era of ABPP began in the 1990s with the development of ABPs compatible with proteomic workflows, and the first applications of ABPP were reported during this decade in studies of proteases. In 1999, the Cravatt lab formally introduced the term "activity-based protein profiling," establishing a framework for systematic functional proteomics. Subsequent work by Ben Cravatt at The Scripps Research Institute, Matthew Bogyo at Stanford University, and Herman S. Overkleeft at Leiden University helped define the field through the design of probes targeting serine hydrolases, cysteine proteases, oxidoreductases, human cytochrome P450s and other enzyme families. Since its inception, ABPP has expanded rapidly, with bibliometric analyses documenting exponential growth in publications and widespread adoption across North America, Europe, and Asia. Advances in mass spectrometry and protein separation technologies further accelerated the integration of ABPP into proteomic research, enabling the characterization of enzyme activity on a global scale and establishing ABPP as a cornerstone of functional proteomics.
Accumulation of amyloid proteins in the gastrointestinal system may be caused by a wide range of amyloid disorders and have different presentations depending on the degree of organ involvement. Potential symptoms include weight loss, diarrhea, abdominal pain, heartburn (gastrointestinal reflux), and GI bleeding. Amyloidosis may also affect accessory digestive organs including the liver, and may present with jaundice, fatty stool, anorexia, fluid buildup in the abdomen, and spleen enlargement. Accumulation of amyloid proteins in the liver can lead to elevations in serum aminotransferases and alkaline phosphatase, two biomarkers of liver injury, which is seen in about one third of people. Liver enlargement is common. In contrast, spleen enlargement is rare, occurring in 5% of people. Splenic dysfunction, leading to the presence of Howell-Jolly bodies on blood smear, occurs in 24% of people with amyloidosis. Malabsorption is seen in 8.5% of AL amyloidosis and 2.4% of AA amyloidosis. One suggested mechanism for the observed malabsorption is that amyloid deposits in the tips of intestinal villi (fingerlike projections that increase the intestinal area available for absorption of food), begin to erode the functionality of the villi, presenting a sprue-like picture.
Amanda Grace Paulovich is an oncologist, and a pioneer in proteomics using multiple reaction monitoring mass spectrometry to study tailored cancer treatment. Paulovich received a BS in Biological Sciences from Carnegie Mellon University in 1988, a PhD in Genetics from University of Washington in 1996, under the direction of Leland Hartwell. She also received a MD from University of Washington in 1998. Follow her residency in Internal Medicine at Massachusetts General Hospital, she also completed a Postdoctoral Fellowship in Computational Biology at the Massachusetts Institute of Technology Whitehead Center for Genomic Research in 2003, and a Fellowship in Medical Oncology at the Dana Farber Cancer Institute in 2004.
The structure of CARD11 involves multiple domains that impact the protein's ability to activate BCL10 and NF-κB activity. CARD11 has a CARD domain, a serine-threonine rich region, is associated with the N-terminus, which is essential for NF-κB signaling activity. The region following the CARD domain is highly coiled. In deleting the CARD domain, all NF-κB signaling activity was prevented. The CARD domain on CARD11 interacts with the CARD domain on BCL10 to initiate the signaling pathway. On the C-terminus of CARD11 there is the MAGUK domain that is associated with the cell membrane. This domain is often referred to as the inhibitory domain. Protein kinase C activates CARD11 by phosphorylating serine residues within the inhibitory domain. CARD11 has been shown to interact with BCL10. This interaction occurs between the CARD domain on BCL10 and the CARD domain on CARD11, and results in signal propagation and NF-κB activation. Human CARD11 genome location and CARD11 gene details page in the UCSC Genome Browser.
The marine sulfur cycle is driven by sulfate reduction because hydrogen sulfide is oxidized by microbes for energy or is oxidized abiotically. Dissimilatory sulfate reduction is driven by the degradation of buried organic matter and anaerobic oxidation of methane (AOM) both of which produce carbon dioxide. At depths where sulfate is depleted, methanogenesis is prevalent. At the sulfate-methane transition zone (SMTZ), the upwelling of methane produced by the methanogens is met by the anaerobic methanotrophic archaea in the SMTZ which oxidize it using sulfate as an electron acceptor. More sulfate is present at the SMTZ than methane. A 4:1 ratio of sulfate: methane is observed and the excess sulfate is directed towards organic matter degradation. Syntrophic aggregates of sulfate reducers and methanotrophs have been discovered and the underlying mechanisms observed include direct interspecies electron transfer using large multi heme complexes.
Sources: en.wikipedia.org
Most clinical antibiotics were found during the "golden age of antibiotics" (1940s–1960s). Actinomycin was the first antibiotic isolated from Streptomyces in 1940, followed by streptomycin three years later. Antibiotics from Streptomyces isolates (including various aminoglycosides) would go on to comprise over two-thirds of all marketed antibiotics. Streptomyces-derived antibiotics include: Clavulanic acid (Streptomyces clavuligerus) is used in combination with some antibiotics (such as amoxicillin) to weaken bacterial-resistance. Novel anti-infectives being developed include the guadinomines (from Streptomyces sp. K01-0509), inhibitors of the type III secretion system. Non-Streptomyces actinomycetes, filamentous fungi, and non-filamentous bacteria, have also yielded important antibiotics. Nystatin (Streptomyces noursei), amphotericin B (Streptomyces nodosus), ossamycin (Streptomyces hygroscopicus), and natamycin (Streptomyces natalensis) are antifungals isolated from Streptomyces.
alpha, beta amylases phosphorylases starch debranching enzyme (DBE) There are enzymes that are involved in the synthesis and degradation of amylopectin that have isoforms that display different relationships with proteins and other enzymes. For example, there are many versions of SS (starch synthase). Even the third isoform (SS-III) has two different versions. It is believed that SS-I and SS-II both have a role in elongating the chains of amylopectin branches. SS-IV is also thought to be responsible for the leaf-like structure of starch granule clusters.
Mike Evans tied the record for consecutive seasons with at least 1,000 receiving yards, with 11. He shares this record with Jerry Rice. Evans also extended his own record of most such seasons to start his career. Aaron Rodgers became the fifth player to have 500 passing touchdowns. Trey McBride set the record for most receptions by a tight end in his first three seasons, with 221. The previous record of 216 was held by George Kittle. The Buffalo Bills became the first team to score at least 30 rushing touchdowns and at least 30 passing touchdowns in a season. Wild Card Round
It is important for MADD patients to maintain strength and fitness without exercising or working to exhaustion. Learning this balance may be more difficult than normally, as muscle pain and fatigue may be perceived differently from normal individuals. Symptomatic relief from the effects of MADD may sometimes be achieved by administering ribose orally at a dose of approximately 10 grams per 100 pounds (0.2 g/kg) of body weight per day, and exercise modulation as appropriate. Taken hourly, ribose provides a direct but limited source of energy for the cells. Patients with myoadenylate deaminase deficiency do not retain ribose during heavy exercise, so supplementation may be required to rebuild levels of ATP. Creatine monohydrate could also be helpful for AMPD patients, as it provides an alternative source of energy for anaerobic muscle tissue and was found to be helpful in the treatment of other, unrelated muscular myopathies. Inborn Errors of Metabolism Metabolic Myopathies Purine Nucleotide Cycle
Adenylyl-sulfate reductase (glutathione) (EC 1.8.4.9) is an enzyme that catalyzes the chemical reaction AMP + sulfite + glutathione disulfide ⇌ {\displaystyle \rightleftharpoons } adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
Sources: en.wikipedia.org
The cytochrome b5 reductase enzyme contains a typical oxidoreductase structure with a diaphorase binding domain complex for NADH and a FAD-binding domain. A three-stranded linker domain is present, as well as water-mediated hydrogen bonds, in order to biochemically connect the complex. Once cytochrome b5 reductase catalyzes electron transfer, the resulting reduced form of cytochrome b5 reduces the oxidized ferric ion of hemoglobin from Fe 3+ to Fe 2+. Mechanism: NADH + H+ + 2 ferricytochrome b5 -> NAD+ + 2 ferrocytochrome b5
AOD9604 is an orally active, lipolytic 16-amino acid peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the N-terminal end. Initial human trials showed that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. However, later studies failed to demonstrate a sufficient lipolytic effect. Its development was terminated in 2007. Despite its limited efficacy, AOD9604 is still banned in athletes and tested for in competition. AOD9604 appears to enhance lipolysis in mice by upregulating beta-3 adrenergic receptors. Beta-3 adrenergic receptor knockout mice are unresponsive to the lipolytic effects of AOD9604. In a 12 week randomised clinical trial, subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving placebo. Development of AOD9604 was halted following poor efficacy in a later 24 week trial.
Gestational trophoblastic disease like hydatidiform moles ("molar pregnancy") or choriocarcinoma may produce high levels of βhCG due to the presence of syncytiotrophoblasts, part of the villi that make up the placenta, and despite the absence of an embryo. This, as well as several other conditions, can lead to elevated hCG readings in the absence of pregnancy. hCG levels are also a component of the triple test, a screening test for certain fetal chromosomal abnormalities/birth defects. High hCG levels in the maternal serum could suggest Down syndrome, potentially due to continued hCG production by the placenta beyond the first trimester. A study of 32 normal pregnancies came to the result that a gestational sac of 1–3 mm was detected at a mean hCG level of 1150 IU/L (range 800–1500), a yolk sac was detected at a mean level of 6000 IU/L (range 4500–7500) and fetal heartbeat was visible at a mean hCG level of 10,000 IU/L (range 8650–12,200).
Beano is an enzyme-based dietary supplement that is used to reduce gas in the digestive tract, thereby improving digestion and reducing bloating, discomfort, and flatulence caused by gas. It contains the enzyme alpha-galactosidase (α-GAL). It was introduced as a liquid, but that has been discontinued and it is now available only as tablets and strawberry-flavored "Meltaways". Beano is marketed and distributed by Prestige Consumer Healthcare, Inc.
'The All-Species Living Tree' Project (LTP) is a collaboration between various academic groups/institutes, such as ARB, SILVA rRNA database project, and LPSN, with the aim of assembling a database of 16S rRNA sequences of all validly published species of Bacteria and Archaea. At one stage, 23S sequences were also collected, but this has since stopped. Currently there are over 10,950 species in the aligned dataset and several more are being added either as new species are discovered or species that are not represented in the database are sequenced. Initially the latter group consisted of 7% of species. Similar (and more recent) projects include the Genomic Encyclopedia of Bacteria and Archaea (GEBA), which focused on whole genome sequencing of bacteria and archaea.
Sources: en.wikipedia.org
Glutathione is a tripeptide of three amino acids: glutamate, cysteine, and glycine. The cysteine residue provides the sulfhydryl group that gives the molecule its reducing properties.
GSH is the reduced form, which contains a free sulfhydryl group. GSSG is the oxidized form, formed when two GSH molecules join through a disulfide bond. The ratio of GSH to GSSG is often used to assess cellular redox status.
No, glutathione is synthesized endogenously in most cells. It is not classified as an essential nutrient because the body can produce it from amino acid precursors. Dietary sources exist, but they are not required to maintain life.
It is a tripeptide of glutamic acid, cysteine, and glycine. The linkage between glutamate and cysteine uses the gamma-carboxyl group, which is unusual for peptides.